TICKERNERD
Menu
NTLANTLAHealthcare · Biotechnology

NTLA Stock Forecast: Intellia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$13
−2.18% on the day

The 19 Wall Street analysts covering Intellia Therapeutics, Inc. hold a median 12-month price target of $17 — +35.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$1.8B
Ticker Nerd rank
48 / 100
Median analyst target
$17
Analysts covering
19
Total return, dividends reinvested
1W
+3.9%
1M
+17.1%
YTD
+39.7%
1Y
+19.4%
From 52W high
−55.1%
From 52W low
+56.2%
$8
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NTLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Intellia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Accruals
73
Issuance
58
Revisions
48
Quality
42
Value
38
Size
38
Momentum
38
Volatility
21

Growth (94): Sales and profits are climbing, and climbing faster than before.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NTLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NTLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26NTLAHigh $61Median $17Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says19 analysts
10 Buy6 Hold3 Sell
Low $8Median $17High $61

The green dot is the last close — the median target sits +35.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Evercore ISI GroupUpgradeOutperform$16 → $24
16 July 2026Wolfe ResearchDowngradeUnderperform$9.00
16 July 2026Wolfe ResearchDowngradeUnderperform—
10 July 2026WedbushMaintainsNeutral$12 → $17
10 July 2026WedbushMaintainsNeutral—
16 June 2026Canaccord GenuityMaintainsBuy—
15 June 2026CitizensReiteratesMarket Outperform—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026WedbushReiteratesNeutral—
13 May 2026BernsteinMaintainsMarket Perform—
13 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy—
12 May 2026WedbushReiteratesNeutral—
28 Apr 2026Canaccord GenuityMaintainsBuy—
28 Apr 2026CitizensMaintainsMarket Outperform—
28 Apr 2026Goldman SachsMaintainsSell—
28 Apr 2026Morgan StanleyMaintainsEqual-Weight—
27 Apr 2026BairdMaintainsNeutral—
27 Apr 2026Chardan CapitalMaintainsBuy—
4 Mar 2026Jones TradingUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NTLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
6
Fundamentals

Intellia Therapeutics, Inc. (NTLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.4×

Cheaper than 88% of US stocks

Price / sales
30.2×

Cheaper than 7% of US stocks

Price / book
2.5×

Cheaper than 41% of US stocks

EV / EBITDA
−3.5×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−46.2%

Higher than 6% of US stocks

Earnings growth (YoY)
−46.2%

Higher than 11% of US stocks

Gross margin
—
Operating margin
−1472.3%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−55.4%

Higher than 20% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NTLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NTLAIntellia Therapeutics, Inc.$1.8B
48
SEPNSepterna, Inc.$1.8B
89
RXRXRecursion Pharmaceuticals, Inc.$1.8B
41
FTREFortrea Holdings, Inc.$1.7B
97
DMRADamora Therapeutics, Inc.$1.9B
46
ANABAnaptysBio, Inc.$1.7B
100
SNDXSyndax Pharmaceuticals, Inc.$1.7B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Intellia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NTLA news & analysis

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlighted CRSP, NTLA, BEAM and EDIT as gene-editing biotech stocks worth watching for long-term gains, noting that they offer distinct opportunities spanning commercial validation, late-stage catalysts and promising early-stage programs.

Why it matters — This item places NTLA among a select group of gene-editing biotechs positioned for long-term attention, signalling that its pipeline and catalysts are being recognised by a research firm.

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 7 Aug 2026neutral

Intellia Therapeutics announced that on August 1, 2026, it awarded inducement grants to eight new employees under its amended 2024 Inducement Plan, serving as a material inducement to their employment.

Why it matters — NTLA watchers would note that the company is making equity-based grants to attract and hire new talent under Nasdaq Listing Rule 5635(c)(4).

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Zacks Investment Research · 7 Aug 2026negative

Intellia Therapeutics reported a second-quarter loss that matched analyst estimates, but revenue fell 46.2% as lower Regeneron collaboration revenues weighed on the top line, causing a revenue miss.

Why it matters — NTLA watchers would track this because a significant revenue decline driven by reduced collaboration income from Regeneron could signal weaker partner-funded milestones and affect the company's near-term financial outlook.

Intellia Therapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Intellia Therapeutics reported that it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

Why it matters — This signals continued clinical progress for NTLA's two most advanced pipeline candidates.

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Intellia Therapeutics' Q2 2026 earnings call, as indicated by the headline. The item simply presents the earnings call transcript content for that quarter.

Why it matters — An NTLA watcher would want to review the transcript for management's discussion of the company's second-quarter 2026 results and outlook.

FAQ

Frequently asked questions about NTLA stock

What is the NTLA stock price forecast for 2026-2027?

The 19 Wall Street analysts covering Intellia Therapeutics, Inc. have a median 12-month price target of $17, with estimates ranging from $8 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NTLA stock a buy right now?

Of the 19 analysts covering Intellia Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Intellia Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NTLA?

As at 22 Aug 2026, Intellia Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will NTLA stock go up?

No one can know that. What the data says: the median 12-month target from 19 analysts implies +35.4% from the last close, and Ticker Nerd's factor model ranks Intellia Therapeutics, Inc. 48 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NTLA stock forecast for 2030?

No analyst covering Intellia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $61 over the next 12 months.

How has NTLA stock performed over the past year?

Intellia Therapeutics, Inc. returned +19.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intellia Therapeutics, Inc. do?

Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform.

What is the latest news on NTLA?

The most recent item we track (Zacks Investment Research, 24 Aug 2026): "4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains". Zacks Investment Research highlighted CRSP, NTLA, BEAM and EDIT as gene-editing biotech stocks worth watching for long-term gains, noting that they offer distinct opportunities spanning commercial validation, late-stage catalysts and promising early-stage programs.

Company

About Intellia Therapeutics, Inc.

Intellia Therapeutics Inc. is a clinical-stage biotechnology company specializing in genome editing therapies based on the CRISPR/Cas9 platform. The company focuses on developing treatments for genetically defined diseases by precisely editing disease-causing genes either directly inside the body (in vivo) or outside the body in patient-derived cells (ex vivo). Its pipeline targets conditions with significant unmet medical need, including transthyretin (ATTR) amyloidosis, hereditary angioedema, sickle cell disease, and various immuno-oncology indications. Intellia Therapeutics Inc. collaborates with major pharmaceutical partners to advance and potentially scale its therapeutic programs, leveraging shared expertise in drug development and commercialization. Operating within the healthcare and biotechnology sector, the company plays a prominent role in the emerging field of gene editing, where its technologies are used to explore one-time, precisely targeted interventions for serious genetic disorders. Intellia Therapeutics Inc. is headquartered in Cambridge, Massachusetts, a key hub for life sciences and biotech innovation.

CEO Dr. John M. Leonard M.D. · 377 employees · United States · https://www.intelliatx.com